Aleksander Chojecki is a Hematology physician affiliated with Levine Cancer Institute. OpenAlex indexes 54 publications with 275 citations (h-index 6); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4525 Cameron Valley Pkwy
Ste 3500
Charlotte, NC 282114369
Telephone
704-302-8300Registry record last updated 15 Jul 2024.
Clinical trials
- Evaluation of the Pathobiology of CALR-mutated MPN Cells
Sponsor: Wake Forest University Health Sciences
- Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CTI BioPharma Corp.Program year20232 payments
- SERVIER PHARMACEUTICALS LLCProgram year20228 payments
- MorphoSys, US Inc.Program year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.1%Kinase inhibitor41.1%Jakafi53%Sprycel11%Bosulif9%Calquence9%Imbruvica9%Iclusig8%Part D<11 patientsAntimetabolite15.2%Hydroxyurea100%Part D≥13 patients+ 4 more classes in this area
Dermatology
12.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.4%Acyclovir100%Part D≥15 patientsAnti-infectives
7.5%Fluoroquinolone Antibacterial3.7%Levofloxacin100%Part D<11 patientsShort-acting sulfonamides3.7%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- B12 and Folate Deficiencies As Outcome Variables Following Allogeneic Transplant
Biology of Blood and Marrow Transplantation
2026 - Treatment patterns and blood count control in 10,112 patients with polycythemia vera
Expert Review of Hematology
2025 - Retrospective review of relapse after allogeneic stem cell transplant for myeloid malignancy.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Voorhees, MD
Levine Cancer Institute
Edward Copelan, MD
Levine Cancer Institute
Nilanjan Ghosh, MD
Levine Cancer Institute
Antoinette Tan, MD
Levine Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”